These studies typically begin with an initial low dose, which is incrementally increased in subsequent cohorts. Each cohort is closely monitored for adverse effects, and the decision to escalate the dose is based on predefined safety criteria. The process continues until the MTD or dose-limiting toxicity (DLT) is identified.
